New drug combo targets tough ovarian cancers
Disease control
Not yet recruiting
This early-stage trial tests two experimental drugs, XmAb541 and XmAb808, in people with advanced ovarian cancer that has come back or spread. The main goal is to see if the combination is safe and find the best dose. About 90 adults with a specific tumor marker (CLDN6) will take…
Phase: PHASE1 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC